bbm-928-a and sandramycin

bbm-928-a has been researched along with sandramycin* in 2 studies

Reviews

1 review(s) available for bbm-928-a and sandramycin

ArticleYear
Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studies.
    Natural product reports, 2007, Volume: 24, Issue:1

    Echinomycin is the prototypical bisintercalator, a molecule that binds to DNA by inserting two planar chromophores between the base-pairs of duplex DNA, placing its cyclic depsipeptide backbone in the minor groove. As such, it has been the focus of an extensive number of investigations into its biological activity, nucleic acid binding and, to some extent, its structure-activity relationships. However, echinomycin is also the parent member of an extended family of natural products that interact with DNA by a similar mechanism of bisintercalation. The structural variety in these compounds leads to changes in sequence selectivity and and biological activity, particularly as anti-tumour and anti-viral agents. One of the more recently identified marine natural products that is moving close to clinical development is thiocoraline, and it therefore seems timely to review the various bisintercalator natural products.

    Topics: Biological Products; Depsipeptides; DNA; Echinomycin; Intercalating Agents; Peptides; Peptides, Cyclic; Quinolines; Quinoxalines

2007

Other Studies

1 other study(ies) available for bbm-928-a and sandramycin

ArticleYear
Synthesis of key sandramycin analogs: systematic examination of the intercalation chromophore.
    Bioorganic & medicinal chemistry, 1998, Volume: 6, Issue:1

    The preparation and examination of 2-22 constituting a systematic study of the chromophore of sandramycin (1) are detailed. Fluorescence quenching studies were used to establish binding constants for 1-24 within calf thymus DNA, within a single high affinity bis-intercalation binding site 5'-d(GCATGC)2, and to establish the preference for sandramycin binding to 5'-d(GCXXGC)2 where XX = AT, TA, GC, and CG. From the latter studies, sandramycin was found to exhibit a preference that follows the order: 5'-d(GCATGC)2 > 5'-d(GCGCGC)2, deltadeltaGo = 0.3kcal/mol > 5'-d(GCTAGC)2, 5'-d(GCCGGC)2, deltadeltaGo = 0.6 kcal/mol although it binds with high affinity to all four deoxyoligonucleotides. The two highest affinity sequences constitute repeating 5'-PuPy motifs with each intercalation event occurring at a 5'-PyPu step. The most effective sequence constitutes the less stable duplex, contains the sterically most accessible minor groove central to the bis-intercalation site, and the ability to accept two gly-NH/TC2 carbonyl H-bonds identified in prior NMR studies. Similarly, the contribution of the individual structural features of the chromophore were assessed with the high affinity duplex sequence 5'-d(GCATGC)2. To a first approximation, the cytotoxic properties were found to parallel trends established in the DNA binding affinities. The exception to this generalization was 4 which lacks the sandramycin chromophore phenol. Although typically 4-10x less potent than sandramycin against leukemia cell lines, it proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of 1 pM-10 nM placing it among the most potent agents identified to date. Additionally, the first disclosure of the HIV-1 reverse transcriptase inhibitory activity of sandramycin (1) as well as that of its key analogs are described and define the chromophore structural features required for their exceptional potency. Two analogs, 18 and 3, roughly maintain the HIV-1 reverse transcriptase inhibitory potency of 1 but exhibit substantially diminished cytotoxic activity (10(2)-10(3)x).

    Topics: Animals; Antibiotics, Antineoplastic; Binding Sites; Cattle; Cell Death; DNA; Female; HIV Reverse Transcriptase; Humans; Hydroxyquinolines; Intercalating Agents; Mice; Oligonucleotides; Peptides, Cyclic; Phenol; Spectrometry, Fluorescence; Structure-Activity Relationship; Tumor Cells, Cultured

1998